WO2022184320A3 - Medical use of cyclic peptides - Google Patents

Medical use of cyclic peptides Download PDF

Info

Publication number
WO2022184320A3
WO2022184320A3 PCT/EP2022/025075 EP2022025075W WO2022184320A3 WO 2022184320 A3 WO2022184320 A3 WO 2022184320A3 EP 2022025075 W EP2022025075 W EP 2022025075W WO 2022184320 A3 WO2022184320 A3 WO 2022184320A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene expression
diseases
syndromes
alleviation
disorders
Prior art date
Application number
PCT/EP2022/025075
Other languages
French (fr)
Other versions
WO2022184320A2 (en
Inventor
Daniel Obrecht
Peter Zbinden
Johann Zimmermann
Original Assignee
Spexis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spexis Ag filed Critical Spexis Ag
Publication of WO2022184320A2 publication Critical patent/WO2022184320A2/en
Publication of WO2022184320A3 publication Critical patent/WO2022184320A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a peptidic CXCR4 inhibitor having a backbone cyclized peptidic compound built up from 16 amino acid residues, and such compounds for the use in a method for the prevention, alleviation or treatment of respiratory diseases and SARS-CoV-2-related diseases, disorders, syndromes or conditions, as well as for reducing CXCL10 gene expression and/or ISG15 gene expression. Moreover, the present invention relates to a pharmaceutical composition and a kit containing the compound for the use in the prevention, alleviation or treatment of these diseases, disorders, syndromes or conditions, as well as for reducing CXCL10 gene expression and/or ISG15 gene expression.
PCT/EP2022/025075 2021-03-03 2022-03-03 Medical use of cyclic peptides WO2022184320A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP21020121 2021-03-03
EP21020121.6 2021-03-03
EP21020274.3 2021-05-22
EP21020274 2021-05-22
EP21020300 2021-06-09
EP21020300.6 2021-06-09

Publications (2)

Publication Number Publication Date
WO2022184320A2 WO2022184320A2 (en) 2022-09-09
WO2022184320A3 true WO2022184320A3 (en) 2022-10-20

Family

ID=81850588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/025075 WO2022184320A2 (en) 2021-03-03 2022-03-03 Medical use of cyclic peptides

Country Status (1)

Country Link
WO (1) WO2022184320A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104090A1 (en) * 2007-02-28 2008-09-04 Polyphor Ag Template-fixed peptidomimetics
WO2012168336A1 (en) * 2011-06-07 2012-12-13 Polyphor Ag Beta - hairpin peptidomimetics as cxc4 antagonists
WO2013182240A1 (en) * 2012-06-06 2013-12-12 Polyphor Ag Beta-hairpin peptidomimetics
WO2021181398A1 (en) * 2020-03-11 2021-09-16 Biolinerx Ltd. Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104090A1 (en) * 2007-02-28 2008-09-04 Polyphor Ag Template-fixed peptidomimetics
WO2012168336A1 (en) * 2011-06-07 2012-12-13 Polyphor Ag Beta - hairpin peptidomimetics as cxc4 antagonists
WO2013182240A1 (en) * 2012-06-06 2013-12-12 Polyphor Ag Beta-hairpin peptidomimetics
WO2021181398A1 (en) * 2020-03-11 2021-09-16 Biolinerx Ltd. Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ASRANI PURVA ET AL: "SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions", MOLECULAR AND CELLULAR BIOCHEMISTRY, SPRINGER US, NEW YORK, vol. 476, no. 2, 16 October 2020 (2020-10-16), pages 675 - 687, XP037363330, ISSN: 0300-8177, DOI: 10.1007/S11010-020-03935-Z *
CHEN CATHERINE Z. ET AL: "Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2", FRONTIERS IN PHARMACOLOGY, vol. 11, 25 January 2021 (2021-01-25), CH, XP055956544, ISSN: 1663-9812, DOI: 10.3389/fphar.2020.592737 *
JUNG MATHIAS ET AL: "Ganodermycin, a novel inhibitor of CXCL10 expression from Ganoderma applanatum", THE JOURNAL OF ANTIBIOTICS, vol. 64, no. 10, 1 October 2011 (2011-10-01), London, pages 683 - 686, XP055956919, ISSN: 0021-8820, Retrieved from the Internet <URL:https://www.nature.com/articles/ja201164.pdf> DOI: 10.1038/ja.2011.64 *
KHALIL BARIAA A. ET AL: "Chemokines and chemokine receptors during COVID-19 infection", COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, vol. 19, 27 January 2021 (2021-01-27), Sweden, pages 976 - 988, XP055956835, ISSN: 2001-0370, Retrieved from the Internet <URL:http://dx.doi.org/10.1016/j.csbj.2021.01.034> DOI: 10.1016/j.csbj.2021.01.034 *
KIM YE JI ET AL: "Consecutive Inhibition of ISG15 Expression and ISGylation by Cytomegalovirus Regulators", PLOS PATHOGENS, vol. 12, no. 8, 1 August 2016 (2016-08-01), US, pages e1005850, XP055956924, ISSN: 1553-7366, DOI: 10.1371/journal.ppat.1005850 *
NEIDLEMAN JASON ET AL: "Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19", MEDRXIV, 5 February 2021 (2021-02-05), pages 1 - 38, XP055954707, Retrieved from the Internet <URL:https://www.medrxiv.org/content/10.1101/2021.01.22.21250054v2.full.pdf> [retrieved on 20220825], DOI: 10.1101/2021.01.22.21250054 *
ZHANG N ET AL: "CXCL10 an important chemokine associated with cytokine storm in COVID-19 infected patients", EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol. 24, no. 13, 1 July 2020 (2020-07-01), pages 7497 - 7595, XP055956820, DOI: 10.26355/eurrev_202007_21922 *
ZIMMERMANN J ET AL: "Dual anti-viral and immunomodulatory activity of the CXCR4 inhibitor Balixafortide (POL6326) in preclinical in vitro and in vivo SARS-CoV2 infection models", SWISS MEDICAL WEEKLY, vol. 151, no. SUPPL. 251, 1 August 2021 (2021-08-01), CH, pages 14S, XP055956841, ISSN: 1424-3997 *

Also Published As

Publication number Publication date
WO2022184320A2 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
WO2011080102A3 (en) Glp-1 analogues and derivatives
WO2005023866A3 (en) Peptides that inhibit complement activation
CA2427227A1 (en) Lactam compound
EA019965B1 (en) Combination of hcv ns3 protease inhibitor with interferon and ribavirin
US20210401751A1 (en) Compositions for treating viral infections and methods for same
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
WO2005061467A3 (en) Piperazine derivatives as bradykinin antagonists
KR102500280B1 (en) Pharmaceutical composition for preventing or treating periodontal disease or dental avulsion by traumatic injury
EA202192925A1 (en) SOLID FORMS OF THE GLYT1 INHIBITOR
EP1571155A4 (en) Peptides and medicinal compositions containing the same
WO2004009625A3 (en) PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF α-SYNUCLEIN-RELATED DISEASES
CN106188267B (en) Ezrin-derived peptides and pharmaceutical compositions thereof
WO2022184320A3 (en) Medical use of cyclic peptides
WO2021205026A3 (en) Pharmaceutical composition for treatment of enveloped dna or rna virus induced infections and disorders
AU2016317574A1 (en) Compositions and methods for the treatment of neurodamage
ATE533776T1 (en) ANALGESIC PEPTIDE ANALOGUE COMPOUNDS DERIVED FROM CROTALUS DURISSUS TERRIFICUS SNAKE VENOM, THEIR USES, COMPOSITIONS AND METHODS OF THEIR PREPARATION AND PURIFICATION
JPWO2021100614A5 (en)
JP6517732B2 (en) DPP-4 inhibitor, blood sugar level elevation inhibitor and food for inhibiting DPP-4
WO2005002500A3 (en) Inhibitors of coronavirus
CN115087457A (en) Peptide compositions and methods for treating tauopathies
MA27474A1 (en) VACCINE
WO2014053481A1 (en) Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza
US20190375791A1 (en) New d-configured cateslytin peptide
US8193147B2 (en) Use of copolymer 1 for treatment of muscular dystrophy
WO2003020749A3 (en) Ncam binding compounds

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22725992

Country of ref document: EP

Kind code of ref document: A2